Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

• Published in: European journal of cancer (1990) Vol. 149; pp. 1 - 10
• Main Authors: Grimmelmann, Imke, Momma, Michael, Zimmer, Lisa, Hassel, Jessica C., Heinzerling, Lucie, Pföhler, Claudia, Loquai, Carmen, Ruini, Cristel, Utikal, Jochen, Thoms, Kai-Martin, Kähler, Katharina C., Eigentler, Thomas, Herbst, Rudolf A., Meier, Friedegund, Debus, Dirk, Berking, Carola, Kochanek, Corinna, Ugurel, Selma, Gutzmer, Ralf
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2021; Elsevier Science Ltd
• Subjects: Blood; Cancer; Colitis; Diabetes; Diabetes mellitus; Diabetes mellitus (insulin dependent); Diabetic ketoacidosis; Glucose; Immune checkpoint inhibitors; Immune-related adverse events; Ipilimumab; Ketoacidosis; Lipase; Nivolumab; Pancreas; Pancreatitis; PD-1 inhibitor; Pembrolizumab; Signs and symptoms; Skin cancer; Thyroiditis; Pembrolizumab; Immune-related adverse events; Nivolumab; Ipilimumab; Diabetes mellitus; Pancreatitis; Immune checkpoint inhibitors; PD-1 inhibitor; Diabetes; Lipase

Immune checkpoint inhibition (ICI) triggers immune-related adverse events (irAEs). The relevance of lipase elevation remains unclear. Skin cancer patients with newly detected serum lipase elevation (at least twofold upper normal limit) or newly diagnosed type I diabetes mellitus upon ICI therapy wer...